Showing results (201-210 of 250) with videos related to
Sort By:
Pageof 25
BMC Cancer|March 30, 2013
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trialsGeorge Fountzilas, Urania Dafni, Mattheos Bobos, et al.Journal of Translational Medicine|February 15, 2017
Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology GroupAmanda Psyrri, Konstantine T Kalogeras, Ralph M Wirtz, et al.NPJ Precision Oncology|July 18, 2024
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumabHelen Gogas, Shruthi Ravimohan, Antara Datta, et al.European Journal of Cancer (Oxford, England : 1990)|May 15, 2017
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysisChristian U Blank, James Larkin, Ana M Arance, et al.European Journal of Cancer (Oxford, England : 1990)|June 6, 2021
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)Helen Gogas, Reinhard Dummer, Paolo A Ascierto, et al.Plos One|October 10, 2015
Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) StudyGeorge Papaxoinis, Vassiliki Kotoula, Zoi Alexopoulou, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2025
Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047Evan J Lipson, Sonia Dolfi, Hao Tang, et al.Cancers|November 9, 2024
Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in EuropeMichael Weichenthal, Joanna Mangana, Iva Gavrilova, et al.Vaccines|September 28, 2021
Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 InfectionMina Psichogiou, Andreas Karabinis, Garyphallia Poulakou, et al.European Journal of Cancer (Oxford, England : 1990)|December 24, 2018
An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring systemJames Larkin, Michael P Brown, Ana M Arance, et al.Pageof 25